(NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today ...
MINJUVI ® (tafasitamab) is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. Tafasitamab incorporates an XmAb ® engineered Fc domain, which mediates B-cell lysis through apoptosis ...
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil
Knight Therapeutics Inc., (TSX: GUD) ('Knight') a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda. has received approval from ...
Apply for scholarships at Nottingham Trent University in 2026! Up to 50% tuition fee help (£15,350) is available to Indian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results